| Kellie Renee Keeney, DPT | |
|
1100 Sherwood Park Dr Ne Ste 140, Gainesville, GA 30501-3426 | |
| (770) 297-7750 | |
| (770) 297-1026 |
| Full Name | Kellie Renee Keeney |
|---|---|
| Gender | Female |
| Speciality | Physical Therapy |
| Experience | 14 Years |
| Location | 1100 Sherwood Park Dr Ne Ste 140, Gainesville, Georgia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063715274 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | PT010058 (Georgia) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Independent Physical Therapy Of Georgia Llc | 2961312244 | 430 |
News Archive
Neuralstem, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to initiate a Phase Ia safety trial to test NSI-189, its first small molecule compound, in major depression. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in depression and other diseases, such as Alzheimer's disease.
A new position statement released today by the Society for Cardiovascular Angiography and Interventions calls for changes in the way quality of percutaneous coronary intervention care is measured and publically reported.
New Northwestern Medicine- research offers one of the first in-depth studies of how physiological changes during pregnancy reduce the effects of a commonly used drug to treat bipolar disorder, making women more vulnerable to recurring episodes. The new findings will help psychiatrists and physicians prevent bipolar manic and depressive symptoms during pregnancy, which are risky for the health of the mother and her unborn child.
International guidelines recommend direct oral anticoagulants over warfarin to prevent stroke for most patients with atrial fibrillation.
Leading immunologists expect to see some clear advances in the fight against tuberculosis, an infectious disease that is widespread the world over. Professor Stefan Kaufmann, Director at the Max Planck Institute for Infection Biology in Berlin, echoed these sentiments at today's launch of the scientific programme for the 64th Lindau Nobel Laureate Meeting at Lindau, Germany.
› Verified 7 days ago
| Provider Name | Independent Physical Therapy Of Georgia Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1780636068 PECOS PAC ID: 2961312244 Enrollment ID: O20040303000396 |
News Archive
Neuralstem, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to initiate a Phase Ia safety trial to test NSI-189, its first small molecule compound, in major depression. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in depression and other diseases, such as Alzheimer's disease.
A new position statement released today by the Society for Cardiovascular Angiography and Interventions calls for changes in the way quality of percutaneous coronary intervention care is measured and publically reported.
New Northwestern Medicine- research offers one of the first in-depth studies of how physiological changes during pregnancy reduce the effects of a commonly used drug to treat bipolar disorder, making women more vulnerable to recurring episodes. The new findings will help psychiatrists and physicians prevent bipolar manic and depressive symptoms during pregnancy, which are risky for the health of the mother and her unborn child.
International guidelines recommend direct oral anticoagulants over warfarin to prevent stroke for most patients with atrial fibrillation.
Leading immunologists expect to see some clear advances in the fight against tuberculosis, an infectious disease that is widespread the world over. Professor Stefan Kaufmann, Director at the Max Planck Institute for Infection Biology in Berlin, echoed these sentiments at today's launch of the scientific programme for the 64th Lindau Nobel Laureate Meeting at Lindau, Germany.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kellie Renee Keeney, DPT 8823 Production Ln, Ooltewah, TN 37363-6511 Ph: (423) 238-7217 | Kellie Renee Keeney, DPT 1100 Sherwood Park Dr Ne Ste 140, Gainesville, GA 30501-3426 Ph: (770) 297-7750 |
News Archive
Neuralstem, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to initiate a Phase Ia safety trial to test NSI-189, its first small molecule compound, in major depression. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in depression and other diseases, such as Alzheimer's disease.
A new position statement released today by the Society for Cardiovascular Angiography and Interventions calls for changes in the way quality of percutaneous coronary intervention care is measured and publically reported.
New Northwestern Medicine- research offers one of the first in-depth studies of how physiological changes during pregnancy reduce the effects of a commonly used drug to treat bipolar disorder, making women more vulnerable to recurring episodes. The new findings will help psychiatrists and physicians prevent bipolar manic and depressive symptoms during pregnancy, which are risky for the health of the mother and her unborn child.
International guidelines recommend direct oral anticoagulants over warfarin to prevent stroke for most patients with atrial fibrillation.
Leading immunologists expect to see some clear advances in the fight against tuberculosis, an infectious disease that is widespread the world over. Professor Stefan Kaufmann, Director at the Max Planck Institute for Infection Biology in Berlin, echoed these sentiments at today's launch of the scientific programme for the 64th Lindau Nobel Laureate Meeting at Lindau, Germany.
› Verified 7 days ago
Jessica Ariel Smith, PT, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 597 S Enota Dr Ne, Gainesville, GA 30501 Phone: 770-219-8218 | |
Mr. Edward Davis Ryan, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1626 Hastings Ct, Gainesville, GA 30504 Phone: 678-936-0343 Fax: 678-450-6931 | |
Mr. Lee Watkins, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 743 Spring St Ne, Gainesville, GA 30501 Phone: 770-219-8200 Fax: 770-219-3862 | |
Sisu Of Georgia, Inc Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 2360 Murphy Blvd, Gainesville, GA 30504 Phone: 770-535-8372 Fax: 770-535-0252 | |
Tori Pou, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 500 Spring St Se Ste 101, Gainesville, GA 30501 Phone: 770-615-7676 | |
Warner Brock, P.T.,CMDT, MBA, CEAS Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 100 Spring St, Suite B, Gainesville, GA 30501 Phone: 770-532-5721 Fax: 770-532-5929 |